News

The funding represents an additional $5.5 million to BioCryst for the development of BCX4430 as a treatment for hemorrhagic fever viruses. The new total NIAID contract amount to

"We are thrilled to begin this collaboration with Dr. Plemper as we broaden our internal efforts to develop RSV non-fusion inhibitor compounds to complement BTA585, our fusion inhibitor

The antibody will be tested in the field of prevention of thrombosis. This is the twelfth therapeutic antibody based on MorphoSys’s technologies that Novartis is evaluating in clinical

This request for filing was based on clinical data from the phase 2/3 study AB10015, which was successful on its pre-specified primary endpoint at the interim analysis (192

These transformative transactions will position AlliancePharma for the next stage of its corporate development. Assuming the completion of these transactions, AlliancePharma will have approximately 100 employees, a network

The designation provides Araim with a seven year marketing exclusivity period against competition, and several incentives such as federal grants, tax credits and a waiver of PDUFA filing

The companies have signed a definitive agreement, which includes an exclusive option for Takeda to acquire Altos starting on the date of the deal and continuing for a

The drug’s second indication in less than a year will let it be used in combination with dexamethasone alone in adults with multiple myeloma who have received at

Firmagon is an antagonist form of androgen deprivation therapy that reversibly binds to the GnRH receptors, inhibiting the production of testosterone immediately. The European Medicines Agency initially approved